Advertisement
Screener

Acumen Pharmaceuticals, Inc. (ABOS) Graph

ABOS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $27.81M; Operating expenses $32.56M; Net income -$32.72M.
  • 2026-03-31: Research and development $16.48M; Operating expenses $21.15M; Net income -$20.74M.
  • 2025-12-31: Research and development $20.53M*; Operating expenses $25.20M*; Net income -$25.14M*.
  • 2025-09-30: Research and development $21.97M; Operating expenses $26.51M; Net income -$26.45M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$27.81M$32.56M-$32.72M
2026-03-31$16.48M$21.15M-$20.74M
2025-12-31$20.53M*$25.20M*-$25.14M*
2025-09-30$21.97M$26.51M-$26.45M
2025-06-30$37.13M$41.75M-$40.95M
2025-03-31$25.27M$30.37M-$28.80M
2024-09-30$27.25M$32.27M-$29.77M
2024-06-30$19.53M$24.38M-$20.54M
2024-03-31$12.45M$17.77M-$14.87M
2023-09-30$11.18M$16.04M-$12.96M
2023-06-30$9.13M$13.48M-$11.61M
2023-03-31$8.71M$13.13M-$11.31M
2022-09-30$8.31M$11.37M-$10.71M
2022-06-30$7.32M$10.41M-$10.15M
2022-03-31$5.99M$9.21M-$9.13M
2021-09-30$1.80M$3.94M-$3.90M
2021-06-30$2.25M$3.44M-$61.36M
2021-03-31$2.58M$3.79M-$27.00M
2020-09-30$2.99M$3.22M-$2.49M
2020-06-30$1.93M$2.19M-$2.04M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$44.29M$53.70M-$53.45M
2025-06-30$62.39M$72.12M-$69.75M
2024-06-30$31.98M$42.16M-$35.41M
2023-06-30$17.85M$26.61M-$22.92M
2022-06-30$13.31M$19.62M-$19.28M
2021-06-30$4.83M$7.23M-$88.36M
2020-06-30$3.98M$4.46M-$4.08M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$84.36M$98.63M-$96.20M
2024-09-30$59.23M$74.42M-$65.17M
2023-09-30$29.02M$42.65M-$35.87M
2022-09-30$21.61M$30.99M-$29.99M
2021-09-30$6.63M$11.17M-$92.26M
2020-09-30$6.97M$7.68M-$6.57M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$104.89M$123.83M$0.00-$121.33M
2024-12-31$93.80M$114.02M$0.00-$102.33M
2023-12-31$42.32M$61.14M$0.00-$52.37M
2022-12-31$32.36M$45.24M$0.00-$42.86M
2021-12-31$12.30M$19.58M$0.00-$100.61M
2020-12-31$8.00M$9.35M$0.00-$7.33M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48